Partner Mike Overly was quoted in an SC Magazine article, “Bipartisan bill aims to generate cyber hygiene best practices,” covering the Promoting Good Cyber Hygiene Act, a cybersecurity bill introduced by the Senate Republication High-Tech Task Force. This proposed bill would outline best cybersecurity practices that would be reviewed, updated and published for public consumption on an annual basis to better prepare and protect individuals against cybercriminal attacks.
Overly explains that “[t]his type of legislation could be argued to create a de facto standard that, if a business follows it, they will be protected from potential liability.”
However, in terms of the bill’s ability to push businesses to improve their cyber hygiene habits, Overly notes that “[the] bill will have absolutely no impact whatsoever on the problem.”
Overly explains that “[t]his type of legislation could be argued to create a de facto standard that, if a business follows it, they will be protected from potential liability.”
However, in terms of the bill’s ability to push businesses to improve their cyber hygiene habits, Overly notes that “[the] bill will have absolutely no impact whatsoever on the problem.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”